JP2022549086A5 - - Google Patents

Info

Publication number
JP2022549086A5
JP2022549086A5 JP2022516299A JP2022516299A JP2022549086A5 JP 2022549086 A5 JP2022549086 A5 JP 2022549086A5 JP 2022516299 A JP2022516299 A JP 2022516299A JP 2022516299 A JP2022516299 A JP 2022516299A JP 2022549086 A5 JP2022549086 A5 JP 2022549086A5
Authority
JP
Japan
Application number
JP2022516299A
Other languages
Japanese (ja)
Other versions
JP2022549086A (ja
JP7771049B2 (ja
JPWO2021053344A5 (https=
Filing date
Publication date
Priority claimed from GB201913603A external-priority patent/GB201913603D0/en
Application filed filed Critical
Publication of JP2022549086A publication Critical patent/JP2022549086A/ja
Publication of JPWO2021053344A5 publication Critical patent/JPWO2021053344A5/ja
Publication of JP2022549086A5 publication Critical patent/JP2022549086A5/ja
Priority to JP2025186669A priority Critical patent/JP2026041728A/ja
Application granted granted Critical
Publication of JP7771049B2 publication Critical patent/JP7771049B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022516299A 2019-09-20 2020-09-18 新化合物 Active JP7771049B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025186669A JP2026041728A (ja) 2019-09-20 2025-11-05 新化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201913603A GB201913603D0 (en) 2019-09-20 2019-09-20 New compounds
GB1913603.5 2019-09-20
PCT/GB2020/052261 WO2021053344A1 (en) 2019-09-20 2020-09-18 New compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025186669A Division JP2026041728A (ja) 2019-09-20 2025-11-05 新化合物

Publications (4)

Publication Number Publication Date
JP2022549086A JP2022549086A (ja) 2022-11-24
JPWO2021053344A5 JPWO2021053344A5 (https=) 2023-09-06
JP2022549086A5 true JP2022549086A5 (https=) 2023-09-06
JP7771049B2 JP7771049B2 (ja) 2025-11-17

Family

ID=68425648

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022516299A Active JP7771049B2 (ja) 2019-09-20 2020-09-18 新化合物
JP2025186669A Pending JP2026041728A (ja) 2019-09-20 2025-11-05 新化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025186669A Pending JP2026041728A (ja) 2019-09-20 2025-11-05 新化合物

Country Status (15)

Country Link
US (2) US12435072B2 (https=)
EP (1) EP4031240A1 (https=)
JP (2) JP7771049B2 (https=)
KR (1) KR20220101071A (https=)
CN (1) CN114786774A (https=)
AU (1) AU2020351301B2 (https=)
BR (1) BR112022003130A2 (https=)
CA (1) CA3152218A1 (https=)
CL (1) CL2022000656A1 (https=)
CO (1) CO2022003091A2 (https=)
GB (1) GB201913603D0 (https=)
IL (1) IL291172A (https=)
MX (2) MX2022003286A (https=)
PH (1) PH12022550564A1 (https=)
WO (1) WO2021053344A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202004094D0 (en) * 2020-03-20 2020-05-06 Vicore Pharma Ab New compounds and uses
GB202013721D0 (en) * 2020-09-01 2020-10-14 Vicore Pharma Ab New compounds
GB202104033D0 (en) * 2021-03-23 2021-05-05 Vicore Pharma Ab New compounds
GB2605148A (en) * 2021-03-23 2022-09-28 Vicore Pharma Ab New compounds
EP4313953A1 (en) * 2021-03-23 2024-02-07 Vicore Pharma AB Selective angiotensin ii receptor ligands
GB202113583D0 (en) * 2021-09-23 2021-11-10 Vicore Pharma Ab New compounds
GB202104038D0 (en) * 2021-03-23 2021-05-05 Vicore Pharma Ab New compounds
MX2024000518A (es) * 2021-07-09 2024-01-31 Vicore Pharma Ab Nuevos compuestos selectivos de angiotensina ii.
CA3247073A1 (en) * 2022-04-06 2025-02-03 Wuhan Humanwell Innovative Drug Research and Development Center Limited Company AT2R AGONIST
IE20230600A3 (en) 2022-12-22 2025-09-24 Vicore Pharma Ab A method of treating a patient diagnosed with an interstitial lung disease
WO2024149712A1 (en) * 2023-01-09 2024-07-18 Vicore Pharma Ab Selective angiotensin ii compounds
CN119504723A (zh) * 2023-08-25 2025-02-25 武汉人福创新药物研发中心有限公司 作为at2r激动剂的噻吩磺酰基氨基甲酸酯
WO2025146172A1 (zh) * 2024-01-03 2025-07-10 武汉人福创新药物研发中心有限公司 一种并环类化合物作为at2r激动剂

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198438A (en) * 1991-05-07 1993-03-30 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted thiophene or furan
US5312820A (en) 1992-07-17 1994-05-17 Merck & Co., Inc. Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines
US5444067A (en) 1993-08-30 1995-08-22 Merck & Co., Inc. Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety
SE9800550D0 (sv) 1998-02-24 1998-02-24 A & Science Invest Ab A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
YU78601A (sh) 1999-05-05 2005-07-19 Aventis Pharma Deutschland Gmbh. 1-(p-tienilbenzil)-imidazoli kao agonisti angiotenzin-(1-7)- receptora, postupak za njihovu proizvodnju, njihova primena i farmaceutski preparati koji ih sadrže
DE19920815A1 (de) 1999-05-05 2000-11-09 Aventis Pharma Gmbh 1-(p-Thienylbenzyl)-Imidazole als Agonisten von Angiotensin-(1-7)-Rezeptoren, Verfahren zu ihrer Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
KR100938817B1 (ko) 2001-05-31 2010-01-26 바이코어 파마 아베 안지오텐신 ⅱ 작용제로 유용한 삼중고리 화합물
CA2449150C (en) 2001-05-31 2011-07-12 Vicore Pharma Ab Tricyclic compounds useful as angiotensin ii agonists
WO2004046141A1 (en) 2002-11-21 2004-06-03 Vicore Pharma Ab New tricyclic angiotensin ii agonists
AU2006235698B2 (en) 2005-04-12 2012-03-29 Vicore Pharma Ab New tricyclic angiotensin II agonists
US8835471B2 (en) 2010-06-11 2014-09-16 Vicore Pharma Ab Use of angiotensin II agonists
KR20150028761A (ko) * 2011-12-16 2015-03-16 타릭스 파마슈티컬스 엘티디. 섬유증 치료용 안지오텐신
KR102230461B1 (ko) 2013-03-15 2021-03-22 유니버시티 오브 써던 캘리포니아 엔지오텐신-관련 질환들의 치료를 위한 방법들, 화합물들 및 조성물들
EP2832357A1 (en) 2013-07-29 2015-02-04 Charité - Universitätsmedizin Berlin Selective AT2 receptor agonists for use in treatment of cachexia
BR112017012337A2 (pt) 2014-12-12 2018-02-27 Vicore Pharma Ab Método para tratamento de doença falciforme, agonista do receptor at2, ou um sal farmaceuticamente aceitável, solvato ou pró- fármaco do mesmo, uso de um agonista do receptor at2, ou um sal farmaceuticamente aceitável, solvato ou pró-fármaco do mesmo, formulação farmacêutica, e, produto de combinação.
WO2016107879A2 (en) 2014-12-30 2016-07-07 Vicore Pharma Ab New use of angiotensin ii receptor agonists
CN107405406A (zh) * 2015-03-02 2017-11-28 维科尔药物公司 用于治疗肺纤维化的血管紧张素ii受体激动剂
WO2017221012A1 (en) 2016-06-21 2017-12-28 Vicore Pharma Ab Methods and compositions for preventing or reducing the risk of cancer treatment-related cardiotoxicity
AR108906A1 (es) * 2016-06-29 2018-10-10 Bristol Myers Squibb Co Heterociclos de biarilmetilo
GB201710906D0 (en) 2017-07-06 2017-08-23 Vicore Pharma Ab Compounds and methods for treating peripheral neuropathy

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
JP2022549086A5 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
JP2023539614A5 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR112023016292A2 (https=)
BR112023011610A2 (https=)
BR112023011539A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)